Semaglutide vs Tirzepatide: Which GLP‑1 Fits Your Weight‑Loss Goals
A clear semaglutide vs tirzepatide comparison overview helps you choose which GLP‑1 aligns with your weight‑loss goals. Clinical trials found greater average weight loss with tirzepatide than semaglutide in direct comparison, a difference many people find meaningful (Aronne et al., SURPASS‑2). You should weigh three practical criteria: efficacy, dosing and titration, and side‑effect patterns. Injection‑site rotation and routine tracking matter too. Tracking makes the difference between guessing and useful notes. Log dose dates, injection sites, symptoms, and weight changes so you can spot trends over weeks. Pepio helps you keep those records in one place, so your shot history and symptom notes stay organized. Users using Pepio report clearer visit preparation and fewer missed doses when using Pepio’s iOS app reminders; Pepio’s web tools are free and privacy‑first while the iOS app adds push notifications and exports. Learn more about Pepio’s approach to helping people track GLP‑1 routines and keep progress organized while you discuss options with your clinician.
Comparison Framework & Pepio as the First Option
When evaluating semaglutide vs tirzepatide, use a clear, practical framework. This semaglutide vs tirzepatide comparison criteria and Pepio tracker framework focuses on outcomes you can measure and track.
Start with five criteria that matter to users and clinicians. Each criterion links to what you should log and why tracking improves decisions. For efficacy, note that tirzepatide shows larger average weight loss and greater A1C reduction in trials compared with semaglutide (SURPASS-2 summary and Aronne et al.). For safety, gastrointestinal and other adverse events vary by drug and dose (Umińska et al.). Track these data points alongside your own symptom and weight logs to see trends that matter to you.
Evaluation Criteria:
- Efficacy (average % weight loss)
- Dosing schedule & flexibility
- Common side-effects & severity
- Injection-site rotation recommendations
-
Tracking & reporting features
-
Option 1: Pepio GLP-1 Tracker
- Central place to log semaglutide or tirzepatide doses, sites, symptoms, and weight
- Pepio’s free iOS app sends push notifications to help prevent missed shots; web tools include a Next Dose Date calculator and calendar reminders
- Visual progress charts help spot trends
- Free web calculators for dose‑to‑unit conversion and reconstitution tools for compounded semaglutide/tirzepatide
-
No medical advice; purely organizational — use Pepio to keep organized, not to make dosing decisions
-
Option 2: Semaglutide (Medication Profile)
- Injectable semaglutide brands Ozempic and Wegovy are weekly; oral semaglutide (Rybelsus) is daily. Injectable dose escalation occurs every 4 weeks per FDA‑label schedules. Use Pepio’s Semaglutide Titration Schedule tool to plan and track dose escalation.
- Proven 15‑20% average weight loss in trials (SURMOUNT-5 summary)
- Typical side-effects: nausea, constipation, food-noise changes
-
Standard injection-site rotation (abdomen, thigh, arm)
-
Option 3: Tirzepatide (Medication Profile)
- Weekly dosing, higher potency
- Up to ~20–22% average weight loss in trials (Aronne et al. and trial summaries)
- Gastrointestinal adverse events are common with both medications; safety profiles vary by dose and population. Discuss individualized risks with your clinician.
- Similar rotation guidelines to semaglutide
Pepio helps you treat tracking as part of care, not as extra work. Users who log doses and symptoms consistently miss fewer shots, see clearer weight trends, and have cleaner notes for clinician visits. Pepio organizes dose history, injection-site rotation, symptom timing, and weight charts in one place. Users can export PDF/CSV reports for clinician visits, reducing gaps and speeding pattern recognition. Pepio’s web tools are free, no‑sign‑up, and privacy‑first; the iOS app is cloud‑synced and adds push notifications and export features. Pepio is for organization and self-tracking only; it does not provide medical advice. Learn more about how Pepio can help you keep dose history, symptom logs, and progress charts together so you bring better notes to your next appointment.
Semaglutide Profile: Efficacy, Dosing, and What to Track
Semaglutide has strong trial evidence for meaningful weight loss and a predictable weekly dosing pattern. In trials such as SURMOUNT‑5, tirzepatide achieved greater average percent weight loss than semaglutide over the study period (for example, tirzepatide ≈20% vs semaglutide ≈12% at study end in trial cohorts). Typical approved dosing for injectable semaglutide starts low and dose increases typically occur every 4 weeks; oral formulations follow a daily schedule (NCBI). Those reported percentages reflect cohort averages and can vary by dose, trial duration, and participant characteristics. Use Pepio’s FDA‑label‑aligned titration schedule generators to plan and log each step.
Gastrointestinal effects are the most common side effects. Pooled trial data report nausea in about 30% of users, vomiting near 10%, diarrhoea around 12%, and constipation near 15% (Wiley Online Library). These symptoms are usually mild to moderate. They often appear during dose escalation and lessen over time.
What to log while on semaglutide
- Dose amount and formulation (injectable or oral)
- Date and time of each dose
- Injection site for shot users
- Any GI symptoms and their timing
- Appetite or “food noise” changes after doses
- Body weight and percentage change
- Missed doses or schedule changes
- Notes for clinician visits
Keep entries concise and consistent. Pepio helps GLP-1 users keep those items in one place so patterns are easier to see. Users using Pepio can organize dose history, symptoms, and weight notes before a follow‑up visit. Pepio's practical tracking approach supports clearer conversations with your clinician.
Contact a healthcare professional for severe, persistent, or worsening symptoms, such as prolonged vomiting, signs of dehydration, severe abdominal pain, or other urgent concerns. Pepio is for organization and self‑tracking only. Pepio does not provide medical advice, diagnosis, or dosing recommendations. Always follow instructions from your clinician, prescriber, pharmacist, or medication label.
Tirzepatide has shown larger average weight loss and greater HbA1c reductions than semaglutide in head‑to‑head trials. In SURPASS‑2 and other comparative studies, tirzepatide produced significantly greater mean weight loss and a larger share of participants reached ≥10% weight loss (Aronne et al., NEJM). Trial summaries also note these efficacy differences alongside safety trade‑offs (Drugs.com).
Trial dosing typically begins at a low weekly dose and escalates through set titration steps up to 15 mg weekly. That stepped approach aims to improve tolerability while reaching an effective dose range used in studies (Drugs.com). Use Pepio’s FDA‑label‑aligned titration schedule generators to plan and log each step.
Gastrointestinal events were the most common adverse effects in trials. Nausea, diarrhea, and vomiting occurred more often than with comparators in SURPASS‑2 (Aronne et al., NEJM). Some analyses also reported higher rates of serious adverse events in certain comparisons, which clinicians review when choosing therapy (Drugs.com). Track symptoms closely and share patterns with your care team.
What to log while on tirzepatide:
- The weekly dose and any titration steps you followed
- Exact date and time of each injection
- Gastrointestinal symptoms and their timing after a shot
- Weight, BMI, and percentage weight change over time
- Any clinician instructions or dose-change notes
- Missed doses, supply remaining, and next refill dates
- Injection site and rotation notes
Keeping a clear record helps you and your clinician assess benefits and tolerability. Pepio helps you organize those entries so dose history, symptoms, and weight trends live in one place. Users using Pepio report easier note sharing at follow‑ups and clearer progress reviews. Learn more about Pepio’s approach to tracking GLP‑1 routines as you compare options.
Pepio is for organization and self‑tracking only. Pepio does not provide medical advice, dosing recommendations, or treatment guidance. Always follow instructions from your clinician, prescriber, pharmacist, or medication label. Contact a healthcare professional if you experience concerning or severe symptoms.
A concise comparison of the trial numbers and what they mean for how you should track doses, symptoms, and weight. These figures come from head‑to‑head trials and summaries, and they are for information only, not clinical guidance.
- Mean weight loss (trial cohorts): Tirzepatide > Semaglutide in head‑to‑head studies (see SURPASS‑2 and SURMOUNT‑5 for study context)
- % achieving ≥10% weight loss (SURPASS‑2): Tirzepatide ~68% vs Semaglutide ~45% in trial populations (Aronne et al. and a trial summary on Drugs.com)
- HbA1c reduction: Tirzepatide larger than Semaglutide in diabetes cohorts; absolute results vary by trial and baseline glycemia (Aronne et al. and comparative analyses in JAMA Internal Medicine)
- GI adverse events (pooled): Nausea rates are broadly similar across agents in some pooled analyses; diarrhea trends higher with tirzepatide in some reports (Umińska et al. and Drugs.com)
- Dosing: Both are administered weekly in common regimens; tirzepatide studies used stepwise titration up to 15 mg, while semaglutide obesity regimens titrate toward 2.4 mg (Drugs.com and StatPearls)
- Tracking implication: Log each titration step, note exact symptom onset and severity after dose changes, and weigh consistently (same scale, time of day). Consistent records matter for long‑term review (Nature Medicine).
These trade‑offs affect what you record. Pepio helps you keep dose history, titration notes, symptom timing, and weight trends in one place. Users using Pepio report easier review before clinician visits and clearer patterns over time. This summary is informational only. Pepio is for organization and self‑tracking and does not provide medical advice; always follow instructions from your clinician, prescriber, pharmacist, or medication label.
Tracking side effects after a semaglutide or tirzepatide shot helps you spot patterns and share clearer notes with your clinician. Gastrointestinal effects are common, so keep concise records and review safety summaries like the one from Umińska et al., MDPI for context. Pepio helps you keep those records in one place so you can focus on trends, not scattered notes.
- Fields to log: dose, date/time, injection site, symptom type, onset time, duration, severity (mild/moderate/severe), appetite/food-noise notes, weight
-
Cadence: during titration log daily; once stable log weekly or after each dose event
-
Use consistent language: same symptom labels and severity scale to spot patterns
-
Prepare notes for clinicians: summarize trends, missed doses, and any persistent or severe events
-
Safety note: contact a healthcare professional for severe, worsening, or concerning symptoms
Use your entries to map timing and frequency of symptoms against dose changes or missed shots. Teams using Pepio keep clearer timelines for follow-ups, which makes clinician conversations more efficient and focused on the facts.
Injection-site rotation means alternating where you inject within approved subcutaneous areas. Common sites are the abdomen, thigh, and upper arm. Semaglutide and tirzepatide use the same subcutaneous sites, so rotation practices match. Rotating helps avoid repeated placements that can cause lumpiness or lipohypertrophy.
Log each shot with the date and site, plus brief notes on tenderness or reactions. A simple date + site entry shows where you injected last and where to rotate next. Pepio helps you keep that log in one place and prepare clear notes for clinician visits. Track your next shot in Pepio to maintain a consistent site history and reduce site confusion. Always follow the instructions from your clinician, prescriber, pharmacist, or medication label.
Choose a GLP‑1 with your clinician, noting tirzepatide often produced larger weight loss in trials (summary on Drugs.com). Regardless of which medication you and your clinician choose, track dose history, symptoms, injection site, and weight to spot patterns and prepare for follow-ups.
Pepio helps you keep those records and set consistent reminders so your routine stays organized. Users who log shots and symptoms get clearer notes for clinician visits. Learn more about Pepio's approach to routine tracking and try saving your next shot there. Pepio is for organization and self‑tracking only. Pepio does not provide medical advice, diagnosis, treatment, dosing recommendations, or protocol recommendations.